Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. [Yahoo! Finance]
Pfizer, Inc. (PFE)
Last pfizer, inc. earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.pfizer.com/investors-overview/default.aspx
Company Research
Source: Yahoo! Finance
In mid-June, Pfizer 's (NYSE: PFE) gene-therapy candidate to treat Duchenne muscular dystrophy (DMD) didn't hit the mark in a late-stage clinical trial; it'd be logical to assume that shares of Sarepta Therapeutics (NASDAQ: SRPT) a biotech focused on developing DMD drugs, would then rise. But that didn't happen -- at least not until Sarepta got a green light for one of its programs from the Food and Drug Administration (FDA) on June 20, causing its stock to soar by 31%. Let's evaluate the situation and determine whether there's an investable opportunity -- or perhaps a threat to your portfolio, if you're already a shareholder of either business. Failing here isn't good news for anyone DMD is a rare, fatal, degenerative, and predominantly hereditary illness that causes progressively worsening muscle weakness. It's typically diagnosed before patients are 5 years old, and there aren't yet any curative treatments, though there are a few interventions to address some of the symptoms.
Show less
Read more
Impact Snapshot
Event Time:
PFE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PFE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PFE alerts
High impacting Pfizer, Inc. news events
Weekly update
A roundup of the hottest topics
PFE
News
- What to know about the XEC Covid variant gaining traction in the U.S. [MSNBC.com]MSNBC.com
- Tax Cuts - An Examination Of The 2017 TCJA Impact [zero hedge]zero hedge
- What to know about the XEC Covid variant [MSNBC.com]MSNBC.com
- Agios cut at Leerink on overhang from Pfizer's Oxbryta withdrawal [Seeking Alpha]Seeking Alpha
- Biopharmaceutical Market Size Projected to Reach USD 17,902.42 Billion by 2032 with 49.60% CAGR – SNS Insider [Yahoo! Finance]Yahoo! Finance
PFE
Earnings
- 7/30/24 - Beat
PFE
Sec Filings
- 9/16/24 - Form 4
- 9/16/24 - Form 4
- 9/16/24 - Form 4
- PFE's page on the SEC website